Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

2 Search results.

Ministry of Health, Ethiopia- Health Center / Clinic / Hospital Delivery Register - Delivery Register

- 7/6/16 - 1 form, 6 itemgroups, 56 items, 1 language

Itemgroups: Personal information, Labor and maternal outcome, Obstetric complications, Newborn outcome, HIV Assessment and Services, Total count

Form provided by Binyam Tilahun. Source: http://www.moh.gov.et/ (Ministry of Health, Ethiopia)

10-valent pneumococcal vaccine in HIV-positive, HIV-exposed and HIV-negative infants - NCT00829010 - Lab Tests (Blood Sample)

- 8/27/19 - 1 form, 3 itemgroups, 14 items, 1 language

Itemgroups: Administrative documentation, Laboratory Tests - Antibody Determination, Laboratory Tests - HIV

Study ID: 111634 Clinical Study ID: 111634 Study Title: A phase III, open, controlled study in South Africa to assess the immunogenicity, safety and reactogenicity of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine administered as a 3-dose (6, 10, 14 weeks) primary immunization course in HIV infected infants, HIV exposed uninfected infants and HIV unexposed uninfected infants followed by a booster vaccination at 9-10 months of age. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00829010 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Pneumococcal vaccine GSK1024850A Trade Name: Tritanrix-HepB/Hib, Rotarix Study Indication: Infections, Streptococcal This phase III trial studies the immunogenicity, safety and reactogenicity of a 10-valent pneumococcal conjugate vaccine in three groups of infants that differ by HIV status: HIV-positive infants, HIV-negative infants who are exposed to the virus (by their HIV-positive mother), and HIV-negative infants who are not exposed. The study consists of Screening at 4-8 weeks of age (only for HIV-positive and HIV-exposed infants without HIV-DNA test) and 10 subsequent Visits over a period of 23 months. There are five study cohorts: HIV-positive and HIV-exposed participants receive the vaccine at Visits 1, 2, 3 (i.e. 6, 10 and 14 weeks of life; primary course) and 5 (9-10 months of age; booster), whereas HIV-negative, unexposed infants are randomly assigned to one of three vaccination schedules: the aforementioned schedule consisting of the primary course and the booster, or the 3-dose primary course only without the booster vaccination, or a different primary course consisting of only two vaccinations at Visits 1 and 3 (6 and 14 weeks of age) followed by a booster at Visit 5 (9-10 months). Visit 1 is scheduled at 6-10 weeks of life. The interval between Visits 1 and 2, 2 and 3, as well as 3 and 4 has to be 28-42 days each. Visit 5 then takes place at 9-10 months of age. The interval between Visit 5 and 6 again has to be 28-42 days. Visit 7 is scheduled at 12-13 months of age, Visit 8 at 15-18 months, Visit 9 at 16-19 months, and the final Visit 10 is performed when the subjects are 24-27 months old. This form contains information on antibody determination and other HIV-related laboratory investigations. For all cohorts, antibody determination is to be performed at Visits 1, 4, 5, 6, 8, 9 and 10, whereas timepoints of HIV-related testing are dependent on Cohort: For Cohort 1 (HIV-pos.), HIV-related testing is to be performed at Visits 1, 5, 8 and 10. For Cohort 2 (HIV-neg., exposed), HIV-related testing is to be performed at Visit 10 (and additionally 2 months post-cessation of breast feeding). For Cohort 3, 4, and 5 (HIV-neg., unexposed infants), HIV-related testing is to be performed at Visits 1 and 10. If clinically indicated, HIV-related testing can also be performed at any other Visit.

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.